Series Pre-A+ The Second Financing completed with Curie Bio. Curie.Bio is a venture capital firm that helps founders discover and develop important new medicines .
Series Pre-A+ Financing completed with Curie Bio Curie Bio 196 Broadway, Cambridge, MA 02139, USA JAPAN AMED Certified VC Curie.Bio is a venture capital firm that helps founders discover and develop important new medicines.
Researchers have reported encouraging results from preclinical studies of SOL-257, an experimental gene therapy designed to address underlying disease mechanisms in ALS. In two mouse models of ALS, the therapy improved motor function and extended survival, suggesting it may help slow disease progression rather than just manage symptoms. These findings
SOLA Biosciences has shared new preclinical proof-of-concept data for SOL-257, an experimental gene therapy aimed at addressing a key biological driver of ALS. The therapy is designed to reduce the harmful effects of misfolded TDP-43, a protein linked to nerve cell damage in many people with the disease. By targeting
